Michał Mazurkiewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michał Mazurkiewicz has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Iwona Sylwia Skrzypczak
Department of Pulmonology, Allergology and Respiratory Oncology, Poznan University of Medical Sciences, Poznan, Poland
2 shared publications - Anita Szwed
Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, Poznań, Poland
1 shared publication - Arkadiusz Majewski
Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland
1 shared publication Joanna Goździk-Spychalska
Department of Pulmonology, Allergology and Respiratory Oncology, Poznan University of Medical Sciences, Poland
1 shared publication- Katarzyna Morańska
Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, Poznań, Poland
1 shared publication - Maciej Cymerys
Department of Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland
1 shared publication
Latest Publications
- Open Access
- 29 August 2025
- Published by Medical Communications Sp. z.o.o. in Aktualności Neurologiczne
- Vol. 25 (1) , 9-13
Neurosarcoidosis: symptoms, diagnosis, and treatment – current state of knowledge
Neurosarcoidosis is an inflammatory disease of unknown aetiology, characterised by the presence of non-caseating granulomas within the nervous system. Its prevalence in patients diagnosed with sarcoidosis is estimated to be approximately 10%. The clinical presentation is ambiguous, with symptoms that may manifest acutely or progress gradually over time. Many of these symptoms mimic those of other diseases, making neurosarcoidosis a diagnostic challenge. No sufficiently sensitive or specific biomarkers are available to enable an accurate diagnosis. A range of diagnostic tests must be performed to exclude other conditions. Histopathological confirmation via biopsy is necessary to make a definitive diagnosis, which is not always possible due to the location of lesions and the potential risk of complications associated with performing a biopsy. Once a diagnosis is established, regular follow-up examinations are necessary to monitor disease activity and assess the progression of changes. The optimal treatment strategy depends on the patient’s current clinical status and the potential risk of side effects. Three main lines of treatment for neurosarcoidosis have been described. Treatment selection should also take into account the ability of medications to cross the blood–brain barrier. Treatment response, severity of the disease at the time of diagnosis, and lesion location within the nervous system all influence the prognosis. With appropriate treatment, the majority of patients achieve either complete or partial remission. Therefore, neurosarcoidosis requires multidisciplinary specialist care and a comprehensive approach to each patient.
- 29 August 2025
- Published by Medical Communications Sp. z.o.o. in Aktualności Neurologiczne
- Vol. 25 (1) , 9-13
Open AccessNeurosarcoidosis: symptoms, diagnosis, and treatment – current state of knowledge
Neurosarcoidosis is an inflammatory disease of unknown aetiology, characterised by the presence of non-caseating granulomas within the nervous system. Its prevalence in patients diagnosed with sarcoidosis is estimated to be approximately 10%. The clinical presentation is ambiguous, with symptoms that may manifest acutely or progress gradually over time. Many of these symptoms mimic those of other diseases, making neurosarcoidosis a diagnostic challenge. No sufficiently sensitive or specific biomarkers are available to enable an accurate diagnosis. A range of diagnostic tests must be performed to exclude other conditions. Histopathological confirmation via biopsy is necessary to make a definitive diagnosis, which is not always possible due to the location of lesions and the potential risk of complications associated with performing a biopsy. Once a diagnosis is established, regular follow-up examinations are necessary to monitor disease activity and assess the progression of changes. The optimal treatment strategy depends on the patient’s current clinical status and the potential risk of side effects. Three main lines of treatment for neurosarcoidosis have been described. Treatment selection should also take into account the ability of medications to cross the blood–brain barrier. Treatment response, severity of the disease at the time of diagnosis, and lesion location within the nervous system all influence the prognosis. With appropriate treatment, the majority of patients achieve either complete or partial remission. Therefore, neurosarcoidosis requires multidisciplinary specialist care and a comprehensive approach to each patient.
- Open Access
- 3 July 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 977-983
Gut microbiota in adults with cystic fibrosis: Implications for the severity of the CFTR gene mutation and nutritional status
- 3 July 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 977-983
Open AccessGut microbiota in adults with cystic fibrosis: Implications for the severity of the CFTR gene mutation and nutritional status
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 18, 1547-1554
C-Reactive Protein and Albumin Levels as Useful Tools for Predicting In-Hospital Outcomes in Polish Nonagenarians
Purpose: The admissions of nonagenarians to internal medicine wards are rising. The aim of this study was to analyse the causes of ward admission and blood and renal parameters as potential mortality predictors in this age group. Patients and Methods: Out of 1140 patients, 111 nonagenarians aged 90+ admitted to the Internal Medicine Ward in one general hospital in Poznan in 2019 were studied. Medical records of these patients were analysed to find factors attributable to the hospitalisation. Results: The leading causes of admission were infections and cardiovascular diseases, and the main causes of death were cardiovascular diseases. Elevated C-reactive protein (CRP) level was a statistically significant death predictor. Equally, decreased albumin level was found to be a mortality predictor. No such relationships were obtained for haematological or renal parameters. Conclusion: Our study uniquely analysed a relatively large group of hospitalised nonagenarians and identified those who need particular attention in the ward by identifying those with the highest risk of death. CRP and albumin levels may serve as useful indicators of in-hospital mortality in this age group.
- 1 September 2023
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 18, 1547-1554
Open AccessC-Reactive Protein and Albumin Levels as Useful Tools for Predicting In-Hospital Outcomes in Polish Nonagenarians
Purpose: The admissions of nonagenarians to internal medicine wards are rising. The aim of this study was to analyse the causes of ward admission and blood and renal parameters as potential mortality predictors in this age group. Patients and Methods: Out of 1140 patients, 111 nonagenarians aged 90+ admitted to the Internal Medicine Ward in one general hospital in Poznan in 2019 were studied. Medical records of these patients were analysed to find factors attributable to the hospitalisation. Results: The leading causes of admission were infections and cardiovascular diseases, and the main causes of death were cardiovascular diseases. Elevated C-reactive protein (CRP) level was a statistically significant death predictor. Equally, decreased albumin level was found to be a mortality predictor. No such relationships were obtained for haematological or renal parameters. Conclusion: Our study uniquely analysed a relatively large group of hospitalised nonagenarians and identified those who need particular attention in the ward by identifying those with the highest risk of death. CRP and albumin levels may serve as useful indicators of in-hospital mortality in this age group.
- 17 December 2021
- Published by Edward Elgar Publishing
- p. 303-305
Mascots
"Mascots" published on Dec 2021 by Edward Elgar Publishing.
- 17 December 2021
- Published by Edward Elgar Publishing
- p. 303-305
Mascots
"Mascots" published on Dec 2021 by Edward Elgar Publishing.